About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Treatment Strategies for Hematocrit Control in PV
By
ASH Conference
366 Videos
FEATURING
Amy Zhou
579 views
January 8, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Related Content
AUTOPLAY
ON
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
06:00
2024 Clinical Case Studies
Clinical Case Review: A Not-So-Sweet Case of Vulvar Ulceration
Feat.
A. Geisler
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
24:27
BMFcases
Experts Discuss Pros and Cons of Treatment Approaches in PV
Feat.
T. Bat,
A. Tefferi
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
19:00
Indy Hematology Review
Waldenstrom’s Macroglobulinemia: Approaching the Newly Diagnosed and…
Feat.
S. Treon
17:05
BMFcases
Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…
Feat.
T. Bat,
A. Tefferi
05:38
GRACE
Epcoritamab in NHL - Incidence and Management of CRS
Feat.
T. Phillips
13:34
EULAR 2023 Insights
EULAR 2023 Insights: From Pathogenesis to Therapy in Sjögren's …
Feat.
H. Bootsma
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
06:51
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…
Feat.
D. Tremblay
31:12
UChicago Medicine
Practice-Changing Abstracts in NHL and HL From ASH 2023
Feat.
S. Smith
17:07
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…
Feat.
M. Minnema
